Aim of this study was to systematically review the literature to assess efficacy and safety of stereotactic radiotherapy (SRT) in combination with immunotherapy for the treatment of melanoma brain metastases (MBM). The literature was searched using PubMed, Scopus, and Embase. Studies comparing SRT plus immunotherapy versus SRT or immunotherapy alone were deemed eligible for inclusion. Two studies showed improved overall survival after SRT plus immunotherapy in melanoma cancer patients with brain metastases. Three studies reported data on LC and DFS showing as SRT plus immunotherapy did not improve local control and DFS rates. G3-G4 toxicity was reported in only one study (20% in the SRT plus immunotherapy group versus 23% in the immunotherapy group). Despite SRT plus concurrent immunotherapy seems associated with possible survival advantage and low >= G3 late toxicity rates, the quality of evidence is very low. Therefore, in patients with brain metastases from melanoma, SRT plus immunotherapy should be evaluated on an individual basis after discussion by a multidisciplinary team.

The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review / Lancellotta, Valentina; Del Regno, Laura; Di Stefani, Alessandro; Fionda, Bruno; Marazzi, Fabio; Rossi, Ernesto; Balducci, Mario; Pampena, Riccardo; Morganti, Alessio Giuseppe; Mangoni, Monica; Lebbe, Celeste; Garbe, Claus; Longo, Caterina; Schinzari, Giovanni; Tagliaferri, Luca; Peris, Ketty. - In: LA RADIOLOGIA MEDICA. - ISSN 1826-6983. - 127:7(2022), pp. 773-783. [10.1007/s11547-022-01503-7]

The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review

Pampena, Riccardo;Longo, Caterina;
2022

Abstract

Aim of this study was to systematically review the literature to assess efficacy and safety of stereotactic radiotherapy (SRT) in combination with immunotherapy for the treatment of melanoma brain metastases (MBM). The literature was searched using PubMed, Scopus, and Embase. Studies comparing SRT plus immunotherapy versus SRT or immunotherapy alone were deemed eligible for inclusion. Two studies showed improved overall survival after SRT plus immunotherapy in melanoma cancer patients with brain metastases. Three studies reported data on LC and DFS showing as SRT plus immunotherapy did not improve local control and DFS rates. G3-G4 toxicity was reported in only one study (20% in the SRT plus immunotherapy group versus 23% in the immunotherapy group). Despite SRT plus concurrent immunotherapy seems associated with possible survival advantage and low >= G3 late toxicity rates, the quality of evidence is very low. Therefore, in patients with brain metastases from melanoma, SRT plus immunotherapy should be evaluated on an individual basis after discussion by a multidisciplinary team.
127
7
773
783
The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review / Lancellotta, Valentina; Del Regno, Laura; Di Stefani, Alessandro; Fionda, Bruno; Marazzi, Fabio; Rossi, Ernesto; Balducci, Mario; Pampena, Riccardo; Morganti, Alessio Giuseppe; Mangoni, Monica; Lebbe, Celeste; Garbe, Claus; Longo, Caterina; Schinzari, Giovanni; Tagliaferri, Luca; Peris, Ketty. - In: LA RADIOLOGIA MEDICA. - ISSN 1826-6983. - 127:7(2022), pp. 773-783. [10.1007/s11547-022-01503-7]
Lancellotta, Valentina; Del Regno, Laura; Di Stefani, Alessandro; Fionda, Bruno; Marazzi, Fabio; Rossi, Ernesto; Balducci, Mario; Pampena, Riccardo; Morganti, Alessio Giuseppe; Mangoni, Monica; Lebbe, Celeste; Garbe, Claus; Longo, Caterina; Schinzari, Giovanni; Tagliaferri, Luca; Peris, Ketty
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1285675
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact